SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
Latest Information Update: 22 May 2023
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 17 May 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2022 Planned End Date changed from 1 Jun 2023 to 16 Dec 2023.